|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Testing for HCV Infection: An Update of Guidance for Clinicians and Laboratorians显示文摘 | Getchell Jane P Wroblewski Kelly E DeMaria Alfred Bean Christine L Parker Monica M Pandori Mark Dufour D Robert Busch Michael P Brecher Mark E Meyer William A Pesano Rick L Teo Chong-Gee Beckett Geoffrey A Araujo Aufra C Branson Bernard M D | 2013 | MMWR. Morbidity and Mortality Weekly Report2013，，18： | 3 |
| 2 | Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study显示文摘 | Mark S Pearce Jane A Salotti Mark P Little Kieran McHugh Choonsik Lee Kwang Pyo Kim Nicola L Howe Cecile M Ronckers Preetha Rajaraman Alan W Craft Louise Parker Amy Berrington de González | 2012 | The Lancet . 2012 (9840)2012，，： | 3 |
| 3 | B lymphocytes regulate airway granulocytic inflammation and cytokine production in a murine model of fungal allergic asthma显示文摘到真菌的促进感受性经常导致是特别地困难的临床上设法的气喘的一种严重形式,导致在这些病人的增加的病态和住院。尽管 B 淋巴细胞可能通过 IgE 的生产加重气喘症状,这些房间可能也在对吸入的真菌的保护的反应是重要的。通过 cytokine 版本和 T 房间相互作用,这些淋巴细胞可能也影响航线墙纤维变性的发展和维护。J H −/− 老鼠为抗体的重链部件缺乏 JH 基因,它为 B 房间功能和幸存是批评的。这些动物在很多有免疫力的回答便于 B 淋巴细胞的角色的说明;然而, J H −/− 老鼠没被用来学习真菌的过敏症。在这研究,我们用曲霉属菌 fumigatus 检验了 B 淋巴细胞的角色模仿被环境真菌的暴露触发的人的航线疾病的鼠科的真菌的高空过敏症模型。我们在敏化的野类型的 BALB/c 和 J 暴露于的 H −/− 老鼠重复了真菌的暴露并且没在大航线附近在航线 hyperresponsiveness,全面肺的发炎或骨胶原免职发现差别。然而, Th2 类型 cytokines IL-4 和 IL-13 的层次显著地在 J 相对 BALB/c 控制的 H −/− 鼠标。由对比,煽动性的 cytokines IL-17A 和 IL-6 的层次显著地在 J H −/− 动物,并且有显著地更柔韧的航线嗜曙红血球过多和 neutrophilia 比在控制动物。一起拿,这些调查结果表明淋巴细胞帮助在肺的分隔空间调整 granulocytic 回答到真菌的暴露的那 B。 | Sumit Ghosh Scott A Hoselton Scott V Asbach Breanne N Steffan Steve B Wanjara Glenn P Dorsam Jane M Schuh | 2015 | Cellular & Molecular Immunology2015，12，2： | 2 |
| 4 | Older patients with colon cancer: is adjuvant chemotherapy safe and effective? 显示文摘 | Amit A Jane P | 2003 | J Am Geriatr Soc2003，51，4： | 1 |
| 5 | Double Immunocytochemical labeling of cell and tissue samples with monoclonal anti bromodeoxyuridine显示文摘 | Magaud J P Sargent I Jane Clarke P | 1989 | JHistochem Cytochem1989，37，10： | 1 |
| 6 | Mechanical and thermal properties of extruded soy protein sheets显示文摘 | J Zhang P Mungara J Jane | 2001 | Polymer2001，42，： | 1 |
| 7 | Absorptive capacity,learning,and performance in international joint ventures显示文摘 | P J LANE JANE E SALK MARJORIE A LYLES | | 0，，08： | 1 |
| 8 | High performance liquid chromatography of barley proteins: relative quantities of hordein fractions correlate with malt extract显示文摘 | JANES P W SKERRITT J H | 1993 | J Inst Brew1993，99，： | 1 |
| 9 | Polysaccharide colloidal particles as delivery systems for macromolecules显示文摘 | Janes KA Calvo P Alonso MJ | 2001 | Adv Drug Deliv Rev2001，47，： | 1 |
| 10 | Mechanical and Thermal Properties of Extruded Soy Protein Sheets显示文摘 | Zhang J Mungara P Jane J | 2001 | Polymer2001，42，： | 1 |
| 11 | Polysaccharide colloidal particles as delivery systems for macromolecules 显示文摘 | Janes KA Calvo P Alonso MJ | 2001 | Adv Drug Deliv Rev2001，47，1： | 1 |
| 12 | Light regulation of sink metabolism in tomoto fruit growth and sugar accumulation显示文摘 | Guan H P Janes H W | | 0，，： | 1 |
| 13 | Chitosan nano- particles as delivery systems for doxorubicin 显示文摘 | Janes K A Fresneau M P Marazuela A | 2001 | Journal of Controlled Release2001，73，2： | 1 |
| 14 | Mechanical and Thermal Properties of Extruded Soy Protein Sheets显示文摘 | Zhang J Mungara P Jane J | 2001 | Polymer2001，42，6： | 1 |
| 15 | Polysaccharide colloidal particles as delivery systems for macromolecules显示文摘 | Janes KA Calvo P Alonso M J | 2001 | Adv Drug Deliv Rev2001，47，： | 1 |
| 16 | Kawasaki syndrome显示文摘 | Jane C Burns Mary P Glodé | 2004 | The Lancet2004，，9433： | 1 |
| 17 | The role of total hip replacement in intertrochanteric fractures of the femur显示文摘 | James P Waddell Jane M | 2004 | Clinical Orthroplasty Relate Research2004，429，： | 1 |
| 18 | Guillain-Barre Syndrome 显示文摘 | Jane P Richard AC H | 2004 | Lancet2004，363，： | 1 |
| 19 | Atrazine and Cancer Incidence Among Pesticide Applicators in the Agricultural Health Study (1994-2007)显示文摘 | Beane Freeman Laura E Rusiecki Jennifer A Hoppin Jane A Lubin Jay H Koutros Stella Andreotti Gabriella Zahm Sheila Hoar Hines Cynthia J Coble Joseph B Barone-Adesi Francesco Sloan Jennifer Sandler Dale P Blair Aaron Alavanja Michael C R | 2011 | Environmental Health Perspectives2011，，9： | 1 |
| 20 | L-carnitine supplementation in non-alcoholic fatty liver disease: A systematic review and meta-analysis显示文摘BACKGROUND Non-alcoholic fatty liver disease(NAFLD)dominates the landscape of modern hepatology.Affecting 25%of the general population,there is critical unmet need to identify broadly available,safe and cost-effective treatments.Cumulative evidence in animal and human models suggests that intrahepatic and skeletal muscle fatty acid oxidation is impaired in NAFLD,such that lipid accretion is not matched by efficient utilisation.L-carnitine is a crucial mediator of fatty acid metabolism in vivo,promoting mitochondrial lipidβ-oxidation and enhancing tissue metabolic flexibility.These physiological properties have generated research interest in L-carnitine as a potentially effective adjunctive therapy in NAFLD.AIM To systematically review randomised trials reporting effects of dietary L-carnitine supplementation on liver biochemistry,liver fat and insulin sensitivity in NAFLD.METHODS Search strategies,eligibility criteria and analytic methods were specified a priori(PROSPERO reference:CRD42018107063).Ovid MEDLINE,Ovid EMBASE,PubMed,Web of Science and the Cochrane Library were searched from their inception until April 2019.Outcome measures included serum concentrations of alanine and aspartate aminotransferase(ALT and AST),liver fat and insulin sensitivity assessed by the homeostasis model of insulin resistance(HOMA-IR).A random effects meta-analysis was performed for,ALT,AST and HOMA-IR measures separately.Between-study heterogeneity was measured using I2 statistics.RESULTS Five eligible randomised trials were included in the qualitative and quantitative synthesis(n=338).All of the 5 included trials assessed the effect of L-carnitine on serum ALT,identified from Italy,South Korea and Iran.Weighted mean difference(WMD)for ALT between L-carnitine and control groups after intervention was-25.34 IU/L[95%CI:-41.74-(-8.94);P=0.002].WMD for AST between L-carnitine and control groups was-13.68 IU/L(95%CI:-28.26-0.89;P=0.066).In three studies(n=204),HOMA-IR was evaluated.WMD for HOMA-IR between L-carnitine and control groups was-0.74 units[95%CI:-1.02-(-0.46);P<0.001].Two studies using validated outcome measures reported a significant reduction in liver fat in L-carnitine vs control groups post-intervention(P<0.001).CONCLUSION Pooled results indicate that L-carnitine supplementation attenuates ALT,liver fat and insulin resistance in NAFLD cohorts,confirming a beneficial effect of Lcarnitine for a highly prevalent condition with a growing economic burden. | Prarthana Thiagarajan Jane Chalmers Lu Ban Douglas Grindlay Guruprasad P Aithal | 2020 | World Journal of Meta-Analysis2020，8，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员